Integration of surgery and systemic therapies represents the best management option for most patients with metastatic renal cell carcinoma. Cytoreductive nephrectomy, metastasectomy, and consolidative surgery can all play a vital role in this challenging patient population. Relevant issues in this era relate to the timing of surgery, the role of cytoreduction as systemic therapies become more effective, management of the residual mass, and surgical safety after targeted therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11934-009-0008-9 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!